Plain-English translation of NCT06910657 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is the first human trial of IDOV-Immune, a new cancer treatment made from a specially engineered virus that is designed to infect and kill tumor cells while boosting your body's immune system at the same time. Researchers are testing different doses of this medication to find the safest and most effective dose, and to see early signs of whether it can help shrink advanced cancers that have not responded to standard treatments.
Standard cancer treatments stop working for many patients with advanced tumors, leaving few options. This medication represents a new approach—using a modified virus to attack cancer cells directly while triggering the immune system to fight back—offering hope for patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication on Day 1 of a 28-day cycle. The study uses a dose-escalation design, meaning early participants receive lower doses and later groups receive higher doses based on how well the lower doses were tolerated. Throughout the trial, you will have frequent check-ups including physical exams, blood tests, and imaging scans to monitor your safety and how your body and immune system respond to the treatment.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States
Australia